Committee for Orphan Medical Products invitation to myeloma patients
The European Medicines Agency is currently inviting one or two myeloma patients to participate in a discussion and oral explanation about a potential medicine to treat the disease during the COMP meeting in January (Committee for Orphan Medical Products). The discussions relates to an orphan designation for a potential drug to treat multiple myeloma and the patients designated will be able to contribute from a patient perspective.